

REMARKS

Claims 1-13 and 21-40 are pending before the examiner. It is respectfully requested that this amendment cancelling claims 13 and 31-40 be entered.

According to the Official Action, claims 1-12 and 21-30 are allowed.

According to the Official Action, claims 13 and 31-40 are rejected under 35 USC 112, first paragraph as not being enabling for treating various cancers of colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian, pancreatic, leukemia or glioblastoma in mammals. This rejection is respectfully traversed.


As explained in the previous response, one skilled in the art considering the specification would know that it provides enabling disclosure for claims 13 and 31-40. The claims recite specific cell types, references were supplied which show the relationship between *in vitro* and *in vivo* results and *in vivo* data was submitted. Therefore, it is submitted that claims 13 and 31-40 are enabled and the rejection should be withdrawn.

However, to expedite prosecution claims 13 and 31-40 are being cancelled.

Applicants preserve all rights to file one or more divisional applications for any subject disclosed in this application but not presently claimed.

It is submitted that this application is in condition for allowance and favorable consideration is respectfully requested.

Respectfully submitted,



Janet I. Cord
c/o Ladas & Parry LLP
26 West 61st Street
New York, New York 10023
Reg. No. 33, 778 (212-708-1935)